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Purpose: Nitroglycerin and its effector molecules nitric oxide and cyclic guanosine 
monophosphate d crease smooth muscle cell proliferation i  vitro. We examined the in 
vivo effect of nitroglycerin on intimal hyperplasia. 
Methods: We treated rats after carotid artery balloon injury with nitroglycerin delivered 
paraarterially with a miniosmotic pump for i week. 
Results: High nitroglycerin serum levels were achieved, and the level of cyclic guanosine 
monophosphate in the carotid artery wall was significantly increased (1.48 + 0.37 vs 
0.86 + 0.39 pmol/mg protein; p < 0.05) in the nitroglycerin-treated group. Cellular 
proliferation in the arterial wall was assessed by incorporation of 5-bromo-2'- 
deoxyuridine 6 days after the injury and was lower in the nitroglycerin-treated group 
(15.2 + 3.4 vs 36.3 + 5.5 positive cells/section;p < 0.005). This was due to a decrease 
in the number of proliferating cells in the media (6.3 - 1.2 vs 21.8 +- 4.5; p < 0.005), 
whereas in the budding neointima, the difference in the number of proliferating cells was 
not significant. Neointimal lesions 21 days after the injury did not differ in cross-sectional 
intimal area, in intimal/medial rea ratio, and in cell density. 
Conclusion: Nitroglycerin decreased medial cellular proliferation after balloon injury and 
had no significant effect on intimal proliferation. The size of the neoinfimal lesion was not 
affected by nitroglycerin therapy. (J VAsc SURG 1995;21:499-504.) 
Intimal hyperplasia occurs in response to arterial 
catheter-based and surgical therapeutic interventions 
that inevitably cause arterial injury. After endothelial 
denudation and medial injury, smooth muscle cells 
(SMC) in the media, which normally exist in the 
contractile or quiescent state, undergo a phenotypic 
change to the synthetic or activated phenotype. 1,2 
This is a crucial event that sets the stage for the 
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ensuing process. A neointima is formed by SMC that 
migrate from the media, continue to proliferate in the 
intima, and deposit extracellular matrix. The se- 
quence of  events in the rat carotid artery injury model 
has been well characterized. 3,4 Medial SMC begin to 
proliferate and migrate after 24 hours, medial pro- 
liferation peaks at 48 hours, and maximal intimal 
proliferation occurs after 4 days. Because this prolif- 
erative surge is relatively short-lived, interventions 
during the first week may affect eventual outcome. 
Proliferation persists for more than 8 weeks, but the 
number of SMC in the lesion does not increase 
significantly after 2 weeks. The neointimal lesion is 
evident after 7 days; it is well developed after 2 to 3 
weeks and stabilizes after 3 months. It is estimated 
that eventually 80% of the lesion is composed of 
extracellular matrix. 
Nitroglycerin is a potent vasodilator in common 
clinical use that exerts its hemodynamic effects by 
conversion to nitric oxide (NO) and the generation of  
cyclic guanosine monophosphate (cGMP) in vascular 
SMC. s,6 All three substances have been shown to 
inhibit vascular SMC proliferation and DNA synthe- 
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sis in vitro. 7,s Other actions of nitroglycerin and NO 
such as the vasodilatory effect and inhibition of 
platelet aggregation may also be pertinent o the 
events after arterial injury. 9 Administration of a NO 
donor after arterial injury may therefore be beneficial, 
especially because the normal metabolism of NO in 
this setting is deranged. The major physiologic 
source of NO, the endothelium, is removed, and its 
level in the vessel wall is reduced? ° 
Based on the in vitro studies, our premise was that 
a short, early course of nitroglycerin would be 
effective in suppressing the proliferative surge and 
perhaps inhibit activation of SMC so that the effect 
would persist and manifest i self in the eventual size 
of the neointimal lesion. 
METHODS 
Arterial injury and nitroglycerin treatment. 
Male Sprague-Dawley rats (Harlan Sprague-Dawley, 
Inc., Indianapolis, Ind.) weighing 350 to 400 gm 
were anesthetized with ketamine, xylazine (Rom- 
pun), and acepromazine and underwent balloon in- 
jury of the left common carotid artery with a 2F 
Fogarty balloon catheter (American Edwards Labo- 
ratories, Irvine, Calif.).4 A miniosmotic pump (Alzet 
2001, Alza Corp., Palo Alto, Calif.) was implanted 
subcutaneously in the dorsal aspect of the neck with 
an attached polyethylene cannula (PE-60) that termi- 
nated beside the left common carotid artery. 
To achieve the desired effect we administered a 
very high dose of nitroglycerin. An infusion rate of 10 
~g/min is known to be tolerated by rats and produces 
greater reduction in left ventricular end-diastolic 
volume than lower doses. 11 We tested a rate of 20 
~g/min, which was tolerated by the rats, and used it 
for the experiment. 
The pumps were filled with 2 ml of 10% 
nitroglycerin i  propylene glycol (ICI America Inc., 
Wilmington, DeE) in the treatment group and with 
the same quantity ofpropylene glycol (Sigma Chemi- 
cal Co., St. Louis, Mo.) in the control group. The 
pumps were implanted, and delivery of the medica- 
tion was started immediately before the arterial 
injury. The pumps delivered the medication for 1 
week, after which, in the longer experiments, they 
were removed. 
We confirmed rug delivery by measuring levels 
of nitroglycerin i  the serum and local effect in the 
arterial wall by measuring levels of cGMP, and we 
measured systemic arterial pressure. All three mea- 
surements, which were designed to monitor effects of 
nitroglycerin, were performed on the first and fourth 
day of treatment. 
Assay ofcGMP. Levels ofcGMP were measured 
in the wall of the injured carotid arteries in 
nitroglycerin-treated and control rats on days 1 and 
4 of treatment (four animals per group). The carotid 
arteries were frozen in liquid nitrogen immediately 
after harvesting. After thawing, the arteries were 
homogenized in 6% trichloroacetic acid and centri- 
fuged for 10 minutes at 12,000g. Supernatants were 
extracted twice with 4 volumes of water-saturated 
ether and lyophilized. Each sample was resuspended 
in sodium acetate buffer (0.05 mol/L, pH 6.2), and 
the concentration fcGMP was determined by use of 
the Amersham cGMP assay system (Amersham 
Corp., Arlington Heights, Ill.). The total prote!n 
content of each specimen was determined after 
solubilization of the lyophilized trichloroacetic acid 
pellets in 0.1 mol/L NaOH (37 ° C for 24 hours). 
The protein concentration was measured by use of 
the BCA Protein Assay Reagent (Pierce Chemical 
Co., Rockville, Ill.) with bovine serum albumin as 
standard. 
Measurement of blood pressure. Rats were 
anesthetized with ketamine, Rompun and acepro- 
mazine, i or 4 days after implantation of pump with 
10% nitroglycerin or propylene glycol (four rats per 
group). Through an inguinal incision the common 
femoral artery was exposed and cannulated with a 
21-gauge plastic annula. The pressure was measured 
with a pressure transducer (Statham P23D6; 
Statham, San Juan, P.R.), amplified (Gould 114132- 
10, Cleveland, Ohio), and recorded (Linear 486; 
Linear Institution, Irvine, Calif.). These animals did 
not undergo baUoon injury and were used solely for 
blood pressure measurement. 
Assay of nitroglycerin serum level. Serum 
samples (3 to 4 ml) were removed I and 4 days (three 
animals at each time point) after initiation of 
nitroglycerin therapy. Serum levels of the medication 
were measured by gas chromatography with electron 
capture detection by National Medical Services Inc. 
(Willowgrove, Pa.). 
Assessment of cellular proliferation rate. SMC 
proliferation was measured 6 days after the injury (10 
rats per group) as described. 12Eighteen hours before 
harvesting of the arteries, the rats were given 
5-bromo-2'-deoxyuridine (BrdU) (Sigma Chemical 
Co.) 100 mg/kg and 2'-deoxycytidine (dC) (Sigma 
Chemical Co.) 75 mg/kg into a subcutaneous depot 
on the lower back. In addition, BrdU 30 mg/kg and 
dC 25 mg/kg were given intramuscularly 18 and 12 
hours before removal of the tissues. Sections were 
stained with monoclonal mouse anti-BrdU antibod- 
ies (Boehringer Mannheim, Mannheim, Germany) as 
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described. 13BrdU-positive cells were counted under 
microscopy, and the total number in the media and 
the neointima was recorded. The counts on three 
sections from three separate arterial segments were 
averaged for each animal 
Measurement of intimal lesion. Rats were 
killed 21 days after the injury (10 animals per group) 
and underwent perfusion-fixation through the ab- 
dominal aorta with 4% paraformaldehyde at a 
pressure of 100 mm Fig. Both carotid arteries were 
harvested, and three separate segments from the 
injured artery were fixed and embedded in paraffin. 
Sections measuring 5 p~m were stained with 
hematoxylin-eosin and were photographed tinder 
light microscopy. The intimal and medial areas were 
measured by tracing on a digitizer tablet and the 
computer software package Vidas, Videoplan (Kon- 
tron Bildanalyse, Instruments, Inc., Everett, Mass.). 
Cell density was estimated by relating the number of 
nuclear profiles in the neointima to intimal cross- 
sectional area. 
Statistics. Data are reported as mean + SEM. 
Comparison of group means was performed with the 
unpaired, two-tailed t test. Ap  < 0.05 was consid- 
ered significant. 
RESULTS 
Nitroglycerin administration did not affect the 
health of the animals. Weight gain and food and 
water intake remained normal, and no death was 
related to the treatment. No significant difference was 
found in the systemic arterial blood pressure 36 hours 
(85 -- 3 mm Hg in the nitroglycerin group and 
86 -+ 2 mm Fig in the control group) and 4 days 
(86 -- 3 mm Hg in the nitroglyc~erin and in the 
control group) after initiation of therapy. Nitroglyc- 
erin serum levels measured 1 and 4 days after 
placement of the pump were very high in the 
nitroglycerin-treated group (180.5 _ 4.4 ng/ml). 
Levels of cGMP in the arterial wall were significantly 
higher in the nitroglycerin-treated group (14.8 - 
0.4 pmol/mg protein) than in the control group 
(8.6 +_ 0.4 pmol/mg protein) 1 and 4 days after 
initiation of treatment (p < 0.05). 
Cellular proliferation in the arterial wall 6 days 
after the injury was measured by cellular incorpora- 
tion of BrdU and was lower in the nitroglycerin- 
treated group (15.2 + 3.4 vs 36.3 +_ 5.5 positive 
cells/section; p < 0.005) (Fig. 1). This difference 
was mostly due to a decrease in the number of 
proliferating cells in the media (6.3 _+ 1.2 vs 
21.8 _+ 4.5; p < 0.005) (Fig. 2). The number of 
proliferating cells in the neointima in the nitro- 
Cells/section 
40 
3 
2 
1 
Media + Intima Media Intima 
Fig. 1. Cellular proliferation in the arterial wall 6 days 
after balloon injury (mean _+ SE) in nitroglycerin-treated 
(n = 10, dark bars) and control (n = 10, l~qht bars) group. 
Reduction (p < 0.005) in proliferation i  entire arterial 
wall (left bars) was seen in nitroglycerin-treated group. This 
was mostly due to inhibition of proliferation (p < 0.005) 
in media (middle bars), whereas in neointima, difference in
number of proliferating cells was not significant (right 
bars). 
glycerin-treated group was lower, but the difference 
was not significant. Neointimal lesions 21 days 
after the injury did not differ in cross-sectional 
intimal area (0.107 + 0.011 and 0.109 + 0.015 
mm2; NS), in intimal/medial rea ratio (0.56 -+ 0.08 
and 0 .54_  0.05; NS), or in the nitroglycerin- 
treated and control groups, respectively (Fig. 3). Cell 
density in the neointimal lesions was not different 
between the groups. 
DISCUSSION 
Nitroglycerin is a drug in common clinical use 
that serves as a donor of NO o NO, which has been 
identified as endothelium relaxing factor, is normally 
secreted by the endothelium, 14a6 and its level de- 
creases after endothelial denudation. NO production 
in SMC is induced, but its level does not reach normal 
preinjury level. 17 It appears therefore appropriate to 
administer aNO donor in this setting. 
In addition to the reported antiproliferative 
activity of nitroglycerin and its derivatives, its va- 
sodilatory effect may be beneficial in intimal hyper- 
plasia. An abnormality in relaxation of the injured 
arterial segment is observed after the injury, which 
persists for 4 to 8 weeks, ls,19 Although the relation- 
ship between arterial spasm after balloon injury and 
intimal hyperplasia has not been clarified, several 
clinical studies have shown that coronary spasm as 
seen in variant angina, or as induced by ergonovine 
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Fig. 2. Histologic sections of common carotid arteries 6 
days after balloon injury. Arteries were harvested after 
administration f BrdU and were stained with a monoclo- 
nal anti-BrdU antibody. Proliferating cellsthat have 
incorporated BrdU appear dark. Internal elastic lamina is 
indicated with arrow. A, Active medial proliferation in 
control group. No cells are seen in intima. B, Active intimal 
proliferation i  control group. Few BrdU-positive cells are 
seen in inner media underneath internal elastic lamina. C, 
Active intimal proliferation i nitroglycerin-treated group. 
On this section no BrdU-positive cells are seen in media. 
or hyperventilation, is associated with a higher rate 
of restenosis. 2°22 Reversal of this spasm by nitro- 
glycerin may affect the course of intimal hyper- 
plasia. An additional effect of nitroglycerin that 
we did not address but that may be relevant o the 
Intimal area (mm =) 
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Fig. 3. Size of neointimat lesion (mean + SE) 21 days 
after balloon i jury in nitroglycerin-treated (n = 10, dark 
bars) and control (n = 10, light bars) group. Treatment was 
given for 7 days after balloon injury and was stopped 14 
days before these measurements. There was no significant 
difference between groups when compared as absolute 
cross-sectional area (l ft) or as intimal/medial area ratios 
(right). 
events after vascular injury is its antiplatelet effect. 9
We did not observe a reduction in systemic 
arterial pressure in the nitroglycerin-treated animals 
at 36 hours and after 4 days, even though a very high 
dose of nitroglycerin was used. Although the drug 
was delivered paraarterially, outside the injured left 
common carotid artery, the serum levels that were 
achieved were very high. This lack of effect on 
systemic arterial pressure is not surprising, however, 
because hemodynamic tolerance to nitroglycerin 
given by continuous infusion develops within 10 to 
24 hours, ll,23 At the local level, a supersensitivity to 
nitrovasodilators in the balloon-injured segment has 
been reported. 1°,24 In those segments, nitroglycerin 
was active as demonstrated bythe elevated levels of 
cGMP in the arterial wall. 
In this study nitroglycerin was effective in reduc- 
ing cellular proliferation rate in the arterial wall 6 clays 
after injury. The inhibitory effect of nitroglycerin on 
proliferation was evident in the media and insignifi- 
cant in the neointima. This differential effect may be 
due to the presence of different populations of SMC 
rather than merely a topographic difference. Al- 
though the medication was delivered outside the 
vessel, serum levels were very high, so that a gradient 
effect is unlikely. A differential effect could be 
explained by postulating a retarding effect of nitro- 
glycerin on the activation of SMC and the absence of 
an effect on SMC that have already undergone 
activation and are of the synthetic phenotype. Such a 
mode of action would decrease the number of SMC 
undergoing activation in the media. In the neoin- 
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tima, however, where no SMC are normally present 
and all SMC are of the activated phenotype, no effect 
of nitroglycerin is expected. 
An early inhibitory effect on SMC proliferation, 
as measured here, did not result in reduction of 
neointimal thickness. This is understandable if the 
agent preferentially affects medial proliferation, be- 
cause increased neointimal proliferation persists 
much later 13 and probably determines the eventual 
size of the lesion. A similar phenomenon has been 
observed with inhibitors of basic fibroblast growth 
factor, which decreased early proliferation 2s but not 
late proliferation 26 and did not affect the size of the 
neointimal esion. The site of proliferation was not 
specified in these studies. 
Other explanations for the lack of an effect include 
the development of tolerance and the short duration 
of therapy. Hemodynamic tolerance to nitroglycerin 
develops within 24 hours.n,23 Whether this phenom- 
enon applies to the effects of nitroglycerin on SMC 
proliferation is unclear and its rate has not been 
investigated. The duration of treatment was neces- 
sarily arbitrary and relied on the timing of the early 
proliferative surge. 
In two recent studies, administration of 
L-arginine, a NO precursor, after arterial balloon 
injury resulted in diminution of the neointimal 
lesion. 27,28 One study was performed on rabbit 
aortas, and the effect of L-arginine was reversed by 
coadministration of Nt-nitro-L-arginine methyl es- 
ter. 27 The second study was performed on rat carotid 
arteries, and coadministration of the inhibitor re- 
sulted only in an increase in medial cross-sectional 
area. 28 Na-nitro-L-arginine methyl ester, when given 
alone, did not affect intimal hyperplasia in rats.29 The 
effect the NO donor on the intimal lesions in these 
studies may be related to a longer course of therapy 
(2 weeks) but more likely was related to the 
differences between itroglycerin and L-arginine and 
their specific actions other than NO generation. 
In summary, nitroglycerin reduces the number of 
SMC proliferation in the media but does not affect 
the proliferation of cells that have already migrated 
into the intima. Inhibition of medial proliferation 
alone does not reduce the size of the neointimal 
lesion. 
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